Literature DB >> 28061997

Evaluation of the Pooled Cohort Equations for Prediction of Cardiovascular Risk in a Contemporary Prospective Cohort.

Connor A Emdin1, Amit V Khera2, Pradeep Natarajan2, Derek Klarin2, Usman Baber3, Roxana Mehran3, Daniel J Rader4, Valentin Fuster3, Sekar Kathiresan5.   

Abstract

Most guidelines suggest a baseline risk assessment to guide atherosclerotic cardiovascular disease (ASCVD) prevention strategies. The American Heart Association/American College of Cardiology Pooled Cohort Equations (PCEs) is one tool to assess baseline risk; however, the accuracy of this tool has been called into question. We aimed to examine the calibration and discrimination of the PCEs in the BioImage study, a contemporary multiethnic cohort of asymptomatic adults enrolled from 2008 to 2009 in the Humana Health System in Chicago, Illinois, and Fort Lauderdale, Florida. Our primary end point was hard ASCVD, defined as cardiovascular death, myocardial infarction, and stroke. A total of 3,635 adults who were not on lipid-lowering therapy at baseline were followed for a maximum of 4.6 years. The mean age was 68.6 years; 2000 (55%) participants were women and 935 patients reported being of non-white race (26%). Although 74 ASCVD events were observed over a median follow-up of 2.7 years, 198 events were predicted by the PCEs. The observed event rate was 7.9 per 1,000 participant-years (95% confidence interval [CI] 6.1 to 9.8), whereas the predicted rate by the PCEs was 21 per 1,000 participant-years (95% CI 20.7 to 21.8). This represents an overestimation of 167% (Hosmer-Lemeshow chi-square = 173; p <0.001). With regard to discrimination, the C-statistic of the PCEs was 0.65 (CI 0.58 to 0.71). In an analysis restricted to 3,080 participants without diabetes mellitus and with low-density lipoprotein cholesterol between 70 and 189 mg/dl, the PCEs similarly overestimated risk by 181% (152 predicted events vs 54 observed events; p <0.001). The PCEs substantially overestimate ASCVD risk in this middle-aged adult insured population. Refinement of existing risk prediction functions may be warranted.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 28061997     DOI: 10.1016/j.amjcard.2016.11.042

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  11 in total

1.  2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Donna K Arnett; Roger S Blumenthal; Michelle A Albert; Andrew B Buroker; Zachary D Goldberger; Ellen J Hahn; Cheryl Dennison Himmelfarb; Amit Khera; Donald Lloyd-Jones; J William McEvoy; Erin D Michos; Michael D Miedema; Daniel Muñoz; Sidney C Smith; Salim S Virani; Kim A Williams; Joseph Yeboah; Boback Ziaeian
Journal:  J Am Coll Cardiol       Date:  2019-03-17       Impact factor: 24.094

Review 2.  2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Donna K Arnett; Roger S Blumenthal; Michelle A Albert; Andrew B Buroker; Zachary D Goldberger; Ellen J Hahn; Cheryl Dennison Himmelfarb; Amit Khera; Donald Lloyd-Jones; J William McEvoy; Erin D Michos; Michael D Miedema; Daniel Muñoz; Sidney C Smith; Salim S Virani; Kim A Williams; Joseph Yeboah; Boback Ziaeian
Journal:  Circulation       Date:  2019-03-17       Impact factor: 29.690

3.  Long-Term Risk Prediction for Heart Failure, Disparities, and Early Prevention.

Authors:  Steven Shea; Michael J Blaha
Journal:  Circ Res       Date:  2022-01-20       Impact factor: 23.213

4.  Estimation of Atherosclerotic Cardiovascular Disease Risk Among Patients in the Veterans Affairs Health Care System.

Authors:  Jason L Vassy; Bing Lu; Yuk-Lam Ho; Ashley Galloway; Sridharan Raghavan; Jacqueline Honerlaw; Laura Tarko; John Russo; Saadia Qazi; Ariela R Orkaby; Vidisha Tanukonda; Luc Djousse; J Michael Gaziano; David R Gagnon; Kelly Cho; Peter W F Wilson
Journal:  JAMA Netw Open       Date:  2020-07-01

5.  Performance of the Framingham risk models and pooled cohort equations for predicting 10-year risk of cardiovascular disease: a systematic review and meta-analysis.

Authors:  Johanna A Damen; Romin Pajouheshnia; Pauline Heus; Karel G M Moons; Johannes B Reitsma; Rob J P M Scholten; Lotty Hooft; Thomas P A Debray
Journal:  BMC Med       Date:  2019-06-13       Impact factor: 8.775

Review 6.  Pharmacogenomics and circadian rhythms as mediators of cardiovascular drug-drug interactions.

Authors:  Yong-Jian Geng; Rosalinda Madonna; Ramon C Hermida; Michael H Smolensky
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-05-06

7.  Optimizing Atherosclerotic Cardiovascular Disease Risk Estimation for Veterans With Diabetes Mellitus.

Authors:  Sridharan Raghavan; Yuk-Lam Ho; Jason L Vassy; Daniel Posner; Jacqueline Honerlaw; Lauren Costa; Lawrence S Phillips; David R Gagnon; Peter W F Wilson; Kelly Cho
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2020-08-31

8.  Implementing Cardiovascular Risk Prediction in Clinical Practice: The Future Is Now.

Authors:  Kunal N Karmali; Donald M Lloyd-Jones
Journal:  J Am Heart Assoc       Date:  2017-04-24       Impact factor: 5.501

9.  Impact of 2017 ACC/AHA guidelines on prevalence of hypertension and eligibility for antihypertensive treatment in United States and China: nationally representative cross sectional study.

Authors:  Rohan Khera; Yuan Lu; Jiapeng Lu; Anshul Saxena; Khurram Nasir; Lixin Jiang; Harlan M Krumholz
Journal:  BMJ       Date:  2018-07-11

10.  Development and validation of two SCORE-based cardiovascular risk prediction models for Eastern Europe: a multicohort study.

Authors:  Taavi Tillmann; Kristi Läll; Oliver Dukes; Giovanni Veronesi; Hynek Pikhart; Anne Peasey; Ruzena Kubinova; Magdalena Kozela; Andrzej Pajak; Yuri Nikitin; Sofia Malyutina; Andres Metspalu; Tõnu Esko; Krista Fischer; Mika Kivimäki; Martin Bobak
Journal:  Eur Heart J       Date:  2020-09-14       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.